UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

~~Washington~~WASHINGTON, D.C. 20549

~~_______________~~__________________

FORM 8-K

CURRENT REPORT

~~Pursuant~~PURSUANT toTO ~~Section~~SECTION 13 orOR 15(d) of the ~~Securities Exchange Act of 1934~~

~~Date~~SECURITIES ofEXCHANGE ~~Report~~ACT ~~(Date~~OF ~~of earliest event reported) April 5, 2004~~1934

~~BIO-ONE CORPORATION~~__________________

~~(Exact~~Date ~~name~~ of ~~registrant~~Report as(Date ~~specified~~of inearliest ~~its~~event ~~charter~~reported): November 2, 2004

Bio-One Corporation

(Exact Name of Registrant as Specified in Charter)

Nevada

000-31889

65-0815746

(State or Other Jurisdiction

of Incorporation)

(Commission

File Number)

(I.R.S. Employer

Identification No.)

1630 Winter Springs Boulevard, Winter Springs, Florida 32708

(Address of ~~Principal Executive Office~~ principal executive offices) (Zip ~~Code~~ code)

(407) 977-1005

(Registrant’s telephone number, including area code)

Not Applicable

(Former Name or Former Address, If Changed Since Last Report.)

~~Item~~Check 2.the ~~Acquisition~~appropriate orbox ~~Disposition~~below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of ~~Assets.~~the registrant under any of the following provisions:

Bio-One Corporation, a Nevada corporation (“Bio-One”) consummated a joint venture transaction with Weifang Shengtai Pharmaceuticals Co. Ltd., a company organized under the laws of the People’s Republic of China (“Weifang Shengtai Pharmaceuticals”). Pursuant to the Joint Venture Agreement, Bio-One acquired 51% of a joint venture entity with Weifang Shengtai Pharmaceuticals for a cash payment equal to $2,000,000 and 2,090,000 shares of Bio-One’s Series A Preferred Stock¨

~~Item~~Written 7.communications ~~Financial~~pursuant ~~Statements~~to ~~and~~Rule ~~Exhibits~~425 under the Securities Act (17 CFR 230.425)

~~(c)~~¨

~~Exhibits~~Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

	Exhibit No.		Exhibit Description		Location
	16.1		Stock Purchase Agreement, dated April 5, 2004, by and among Bio-One Corporation, Weifang Shengtai Pharmaceuticals Co. Ltd. and 39 individual shareholders of Shengtai.		Provided herewith

Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)

~~SIGNATURES~~¨

~~Pursuant~~Pre-commencement communications pursuant to ~~the~~Rule ~~requirements~~13e-4(c) ofunder the ~~Securities~~ Exchange Act ~~of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned, hereunto duly authorized~~(17 CFR 240.13e-4(c)

	BIO-ONE CORPORATION
Date: April 19, 2004	By:	/s/ ARMAND DAUPLAISE
		Armand Dauplaise President, Chief Executive Officer, Principal Accounting Officer and Director

Item 4.01. Changes in Registrant’s Certifying Accountant.

3(a)

Previous Independent Accountants

(1)

(i)

Effective November 2, 2004, Tschopp, Whitcomb & Orr, P.A. resigned as the independent certified public accountants of Bio-One Corporation (the “Registrant”), which was necessitated by Tschopp, Whitcomb & Orr, P.A.’s insurance carrier’s reluctance/refusal to insure it for Securities and Exchange Commission work.

(ii)

Tschopp, Whitcomb & Orr, P.A.’s report on the Registrant’s financial statements for the past two fiscal years did not contain an adverse opinion or a disclaimer of opinion, and was not qualified as to uncertainty, audit scope, or accounting principles.

(iv)

During the Registrant’s most recent two fiscal years, as well as the subsequent interim period through September 30, 2004, there were no disagreements on any matter of accounting principles or practices, financial statement disclosure, or auditing scope or procedures, which disagreements if not resolved to their satisfaction would have caused them to make reference in connection with their opinion to the subject matter of the disagreement.

(v)

During the Registrant’s most recent two fiscal years, as well as the subsequent interim period through September 30, 2004, Tschopp, Whitcomb & Orr, P.A. did not advise the Registrant of any of the matters identified in paragraph (a)(1)(v) of Item 304 of Regulation S-K.

(vi)

The Registrant requested Tschopp, Whitcomb & Orr, P.A. to furnish a letter addressed to the Securities and Exchange Commission, stating whether it agrees with the statements made by the Registrant and, if not, stating the respects in which it does not agree.

(b)

New Independent Accountants

On November 30, 2004, the Registrant engaged Moore Stephens Lovelace, PA (“Moore Stephens Lovelace”) as its principal accountant to audit the Registrant’s financial statements. The Registrant did not consult Moore Stephens Lovelace on any matters described in paragraph (a)(2)(i) or (ii) of Item 304 of Regulation S-K during the Registrant’s two most recent fiscal years or any subsequent interim period prior to engaging Moore Stephens Lovelace.

Item 9.01. Financial Statements And Exhibits

(a)

Not applicable

(b)

Not applicable

(c)

Exhibit No. Description

Exhibit	Description	Location
99.1	Letter dated December 3, 2004, from Tschopp, Whitcomb & Orr, P.A.	Provided herewith

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

	BIO-ONE CORPORATION

Date: December 3, 2004	By: /s/ Armand Dauplaise
	Name: Armand Dauplaise
	Its: President, Chief Executive Officer and
	Chief Financial Officer

Filing Compare · BIO ONE CORP